---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-24-000049"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:41:22.505076+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zymeworks reports 9M 2024 net loss $99.2M; cash $374.9M; completes $30M buyback; advances pipeline

## Summary
- Net loss $99.2M for nine months ended Sep 30, 2024 vs $104.2M loss prior year; revenue $45.3M vs $59.1M.
- Cash resources $374.9M (cash, equivalents, marketable securities) as of Sep 30, 2024; projected runway into 2H 2027 including milestones.
- Completed initial $30M share repurchase: 2,545,402 shares at avg $11.79 as of Oct 31, 2024.
- First patient dosed in Phase 1 trial of ZW171 for MSLN-expressing cancers; preclinical data presented for ZW220 and ZW251.
- Director Hollings C. Renton resigns from board effective Dec 10, 2024; not due to disagreement.

## SEC filing metadata
- accession: 0001937653-24-000049
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765324000049/0001937653-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765324000049/zyme-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-24-000049
- JSON: https://secwatch.observer/filing/0001937653-24-000049.json
- Plain text: https://secwatch.observer/filing/0001937653-24-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.